Blinded, Long-Term Safety and Efficacy of Tadalafil in Treatment for Pulmonary Arterial Hypertension.

Conversion From Sildenafil to Tadalafil

“…Additionally, there are long-term data for treatment durability at the FDA-approved dose for tadalafil. 13 It is anticipated that because of these benefits, many patients and clinicians may choose transition from sildenafil to tadalafil therapy. However, there is little reported clinical experience in converting patients from sildenafil to tadalafil.…”

Quality initiatives and models of care in patients with pulmonary arterial hypertension: The time has come!

“…Clinical trials of tadalafil and ambrisentan have shown differences in outcomes in patients receiving placebo that were not improved by subsequent treatment during the time frame examined. (5,6)…”

“…Clinical trials of tadalafil and ambrisentan have shown differences in outcomes in patients receiving placebo that were not improved by subsequent treatment during the time frame examined. (5,6) Although treatment guidelines summarize current knowledge of therapeutic approaches to PAH, based on scientific rigor and evidence from available clinical trials (7,8), the optimal treatment of patients or patient groups is not known. True evidence based recommendations and guidelines could really only be derived from head to head comparison of agents and sequences of treatment, unlikely given the rare nature of the disease.…”